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Risk factorsAbstract Background: Ventilator associated pneumonia (VAP) remains an area of active clinical
research with little data about effect of (VAP) on outcome among patients with acute exacerbation
of chronic obstructive pulmonary disease.
Materials and methods: A prospective study included patients with COPD exacerbation requir-
ing endotracheal intubation for more than 48 h. Clinical assessment and Quantitative culture done
for all patients for the occurrence of VAP.
Results: Out of one hundred ﬁfty two patients 92 patients (60.5%) were with VAP diagnosis.
Their mean age was 56.1 ± 15.02 (38 cases developed early while 54 cases developed late VAP).
Forty eight cases were discharged (54%) while 44 cases (46%) died. In comparing mean age of both
groups 45.08 ± 15.52 and 57.41 ± 16.34 with P value 0.003. Prolonged use of antibiotics, re-
intubation and steroid use are possible risk factors for VAP with signiﬁcant P values 0.03, 0.001,
0.05 respectively. Age above vs. below 60 showed adjusted odds ratio 5.33; 95% conﬁdence interval
1.59–7.83 with P value 0.007. Early vs. late VAP, and prolonged use of antibiotics vs. none showed
signiﬁcant odds ratio 0.32; 95% CI 0.13–0.76, odds ratio 2.85; 95% CI 1.07–7.59 with P values 0.01,
0.04 respectively.
Conclusions: Old age, late onset VAP, re-intubation and prolonged use of antibiotics were pre-
dictors of mortality in VAP patients with AECOPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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Ventilator-associated pneumonia (VAP) is deﬁned as pneumo-
nia occurring more than 48 h after initiation of endotracheal
intubation and mechanical ventilation [1]. It is the commonest
nosocomial infection in the intensive care unit with an inci-
dence ranging from 8–28% in mechanically ventilated patients
and was associated with high morbidity and mortality [2,3].
VAP is usually classiﬁed as early onset when it develops 4 days
from intubation and late onset when it develops after 5 days
and this distinction is signiﬁcant when considering etiological
agents, seriousness, prognosis and therapeutic implications [4].
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality [5]. Its natural
course is characterized by exacerbations which lead to acute
respiratory failure and hospitalization [6]. Although non-
invasive mechanical ventilation (NIV) is ‘‘the standard of
care’’ for management of acute exacerbation of COPD;
mechanical ventilation has a role in large number of cases
because of clinical condition or no improvement on NIV [7].
Endotracheal intubation is performed among these patients
to save life; however, it may be complicated by VAP. Also
COPD is a known risk factor for nosocomial lower respiratory
infections [8,9]. Various factors which may contribute to the
increased risk of lower respiratory infections among these
patients include presence of structural lung damage, repeated
hospitalization, usage of antibiotic, and corticosteroids.
Invasive devices and procedures and antimicrobial therapy cre-
ate favorable media for antimicrobial resistant pathogen to
colonize the aerodigestive tract.
Considering the risk factor of these patients, VAP is
expected to have signiﬁcant adverse outcome on the clinical
course of COPD patients. VAP is still good ﬁeld of clinical
research with little data about effect of VAP on outcome
among patients with acute exacerbation of chronic obstructive
pulmonary disease.
Patients and methods
A prospective, single-center, observational, clinical study in
medical intensive care unit (MICU) and respiratory intensive
care unit over a 12 months period from July 2012 to March
2014. The study was approved from faculty ethics committee.
Because it was an observational study, the requirement for
written informed consent was waived.
Inclusion criteria
Patients with acute exacerbation of COPD were eligible for the
study if placed on mechanical ventilation (MV) for P48 h.
Exclusion criteria
All patients with clinical and radiological signs suggestive of
pneumonia or acute respiratory distress syndrome (ARDS)
secondary to pneumonia on admission were excluded.
Data collection
For each patient the following data are collected: demographic
data, admission diagnosis, co morbid condition, date of MV,date of VAP diagnosis, clinical pulmonary infection score at
the day of VAP diagnosis, possible risk factors for VAP; prior
use of antibiotics >7 days, re-intubation, diabetes mellitus,
recent surgery, oral steroid use >2 weeks. Result of quantita-
tive cultures of endotracheal aspirates in term of identiﬁed
organism and their antimicrobial resistance patterns, duration
of mechanical ventilation, intensive care unit length of stay
(ICU LOS) and patient outcome with either discharge from
ICU or died.
The eligible patients were carefully followed up for signs of
VAP. This included apart from clinical examination, regular
recording of body temperature, observance of tracheal aspirate
appearance, leukocyte count and chest radiograph.
The diagnosis of VAP was based on the American College
of Chest Physicians criteria as an association of a new or pro-
gressive consolidation on chest radiology plus at least two of
the following variables: fever greater than 38 C, leukocytosis
or leukopenia, and purulent secretions (ATS, 2005) [10].
VAP is classiﬁed as follows
Early onset when it develops 3–5 days from intubation; and
late onset when it develops after 5 days. Modiﬁed clinical pul-
monary infection score is calculated at the day of VAP diagno-
sis [11]. Patients with clinical diagnosis of VAP (based on the
above criteria) underwent endotracheal aspirate (ETA).
Quantitative culture done for all patients and the threshold
for ETA was considered as 105 cfu/ml. Growth of any organ-
ism below this threshold was assumed to be colonization or
contamination.
Statistical analysis
All statistical analyses were performed using SPSS version 14.0
software (Chicago, IL, USA). Categorical variables were ana-
lyzed using the c2 test or Fisher’s exact test. Continuous vari-
ables were compared using Student t test or the Mann–
Whitney U test. Multivariate logistic regression analyses were
performed to identify the risk factors. Statistical signiﬁcance
was set to a value of P 6 0.05.Results
During the study period 152 patients were enrolled and divided
into two groups VAP group 92 patients (60%) and without
VAP group 60 patients (40%). The mean age was lower in
VAP patients and most of them were in middle age (52.3%)
and of male gender (63%). ICU length of stay and duration
of mechanical ventilation were statistically signiﬁcantly longer
in VAP group, and so CPIS. Mortality was more in VAP
patients as shown in Table 1.
There were 38 patients (41%) developed early VAP while 54
patients (59%) developed late VAP. Late one was associated
with longer ICU length of stay, duration of MV, higher
CPIS and higher mortality than early VAP and the P value
was highly signiﬁcant as shown in Table 2.
As regards possible risk factors for early vs. late VAP, pro-
longed antibiotic use was more in late VAP with signiﬁcant P
value; also re-intubation was recorded more in late VAP
patients as shown in Table 3.
Table 1 Clinical features of the studied cases.
Characteristics AECOPD with
VAP (92)
AECOPD without
VAP (60)
P
value
Age mean 56.1 ± 15.02 59.03 ± 9.5 0.05
Age <60 62 ± 43.4 28 ± 40.6 0.001
Age >60 30 ± 32.6 32 ± 53.3 NS
Male 58 (63%) 42 (70%) NS
Female 34 (37%) 18 (30%)
ICU LOS
(days)
18.2 ± 8.8 7.4 ± 2.9 0.0001
Duration of
MV
15 ± 8.07 5 ± 3.05 0.0001
CPIS 8.80 ± 1.7 4.23 ± 1.5 0.0001
Death 44 (47.8%) 18 (30%) 0.03
Discharge 48 (52.2%) 42 (70%)
Table 2 Comparison between early and late VAP.
Characteristics Early VAP (38) Late VAP (54) P value
Age mean 45.08 ± 15.52 57.4 ± 16.34 0.003
Age <60 26 ± 43.4 36 ± 40.6 0.01
Age >60 12 ± 31.58 18 ± 53.3 0.05
Male 24 (63%) 34 (63%) NS
Female 14 (37%) 20 (37%)
ICU LOS (days) 12.2 ± 5.9 19.1 ± 7.4 0.0001
Duration of MV 9.15 ± 4.5 19.11 ± 7.4 0.0001
CPIS 7.80 ± 1.4 9.44 ± 1.5 0.0001
Emergency
intubation
10 (26%) 6 (11%) 0.06
ICU intubation 28 (74%) 48 (89%)
Sensitive organism 32 (84%) 26 (48%)
MDR 6 (16%) 28 (52%)
Death 12 (31%) 32 (59%) 0.009
Discharge 26 (69%) 22 (41%)
Table 3 Comparison between early and late VAP as regards
risk factors.
Risk factors Early (38)
patient
Late (54)
patient
P
Value
Previous use of
antibiotics
2 (5.2%) 22 (40.7%) 0.03
Re-intubation 0 10 (18.5%) 0.001
Diabetes M 2 (5.2%) 6 (11.1%) NS
Surgery 0 2 (3.7%) NS
Steroids 4 (10.5%) 0 0.05
Table 4 Univariate logistic regression of factors affecting
occurrence of early vs. late VAP.
Factors Un adjusted odds ratio
(95% CI)
P
value
Male vs. female 1.01 (0.43–2.38) 0.9
Age >40 vs. <40 1.17 (0.38–3.63) 0.7
Co-morbid vs. non 0.61 (0.24–1.51) 0.2
Previous use of antibiotics
vs. non
0.08 (0.02–0.37 0.001
DM vs. non 0.44 (0.08–2.33) 0.3
CPIS >6 vs. 6 0.43 (0.11–1.63) 0.2
ICU vs. emergency 0.35 (0.11–1.07) 0.07
Table 5 Multivariate logistic regression of factors affecting
occurrence of early vs. late VAP: (include only factors with P
value <0.05 in multivariate analysis).
Factors Adjusted odds ratio
(95% CI)
P
value
Previous use of antibiotics vs.
non
0.03 (0.02–0.40) 0.0001
ICU vs. emergency intubation 0.14 (0.03–0.6) 0.008
Table 6 Univariate logistic regression of factors predicting
death in VAP patients.
Factors Un adjusted Odds ratio
(95% CI)
P
value
Early vs. late 0.32 (0.13–0.76) 0.01
Age >60 vs. <40 5.33 (1.59–7.83) 0.007
Co-morbid vs. non 2.08 (0.85–5.05) 0.11
Prolonged use of antibiotics
vs. non
2.85 (1.07–7.59) 0.04
DM vs. non 3.63 (0.69–19.04) 0.13
CPIS >6 vs. 6 0.43 (0.11–1.63) 0.2
ICU vs. emergency 0.9 (0.31–2.64) 0.84
Table 7 Multivariate logistic regression of factors predicting
death in VAP patients: (include only factors with P value
<0.05 in multivariate analysis).
Factors Adjusted odds ratio
(95% CI)
P
value
Age >60 5.89 (0.80–4.60) 0.02
Early vs. late 0.26 (0.09–0.77) 0.03
Prolonged use of antibiotic vs.
non
0.12 (0.03–0.40) 0.001
Risk factors of ventilator associated pneumonia on outcome of acute exacerbation of COPD 801Univariate and multivariate analysis was done for identify-
ing factors affecting occurrence of early vs. late VAP. Prior
antibiotics use and ICU intubation were identiﬁed by ﬁnal
model of multivariate analysis to be more associated with
the occurrence of late VAP (odds ratio <1, and P value
<0.05) as shown in Tables 4 and 5.
Regarding factors predicting death in VAP patients using
Univariate and multivariate analysis late VAP, old age and
prolonged use of antibiotics were identiﬁed by ﬁnal model as
factors predicting death in VAP patients as shown in Tables
6 and 7.Discussion
COPD is a known risk factor for VAP occurrence and is
related to adverse VAP outcomes [12]. In our study VAP
was diagnosed in 60% of patients and this percentage is higher
802 M.Sh. Badawy et al.than the range that was reported for VAP in recent review of
literature which was 9–40% of intubated heterogeneous
patients [13].
Early onset VAP in our study was found to be 41% which is
consistent with ﬁndings in various studies [14,15]. Gram nega-
tive organisms had been identiﬁed in 56% isolates and most of
them were Klebsiella spp. followed by Escherichia coli while
Gram Positive Cocci were responsible for 44% of the isolates
most of them were multi resistant staph aureus. This is in
agreement with Arabi et al., and Lagamayo [16,17].
Most of the VAP patients were of middle age group while
most of non VAP patients were older; more than 60 years.
Most patients were males in both groups. This in concordance
with Al-Dorzi et al. [18]. Our study conﬁrms the associations
of VAP with adverse patients’ outcomes as VAP patients have
longer duration of MV and ICU LOS than non VAP patients
(P value was highly signiﬁcant <0.0001). These ﬁndings are
consistent Ertugrul et al., and Kollef et al. [19,20].
Mortality was higher in VAP patients than non VAP,
nearly 48% of them and this is in agreement with Nseir
et al., and Gupta et al. [12,21]. Those VAP patients who died
were signiﬁcantly older than those who had been discharged (P
value 0.03). There was signiﬁcant difference in gender, ICU
LOS and duration of MV (though was shorter in discharge
group). CPIS was P6 in all patients who died which raises
the question of its value in follow up of VAP patients and pre-
diction of mortality.
Longer ICU LOS, duration of MV and higher mean CPIS
were observed in late onset VAP than early VAP and the dif-
ference was statistically signiﬁcant. Same results were reached
by Raymond et al. [22]. Mortality was higher in L-VAP
(59.26%) than E-VAP (31.58%). The same ﬁnding was
observed by Varun et al. [15].
As regards risk factors for VAP we found that prior antibi-
otic, re-intubation, and DM were recorded at higher percent-
age in L-VAP than E-VAP. Antibiotic prescription is
probably a risk factor for L-VAP in comparison to E-VAP
with signiﬁcant P value 0.001 as antibiotic-resistant bacteria
were isolated more often in L-VAP. Some studies have also
shown that antibiotic prescription protects against E-VAP
[9]. Other investigator found that antibiotic prescription and
prior hospitalization enhance the subsequent infection with
resistant pathogens [23].
Final multivariate logistic regression of factors affecting
occurrence of E-VAP vs. L-VAP identiﬁed prior antibiotic
use and ICU intubation to be associated with the occurrence
of late VAP. It is consistent with Giard et al. [12]. After adjust-
ment for other factors by multivariate analysis for identifying
predictors of mortality in patients with AECOPD with VAP
revealed that old age, re-intubation, and prolonged use of
antibiotics were more prevalent in death group with signiﬁcant
and highly signiﬁcant P value (0.02, 0.03 and <0.001
respectively).
There is some explanation for increased mortality in COPD
patients with VAP in ICU related to respiratory muscle dys-
function, VAP caused by multidrug resistant organism with
high risk of receiving inappropriate initial antibiotic treatment
which has been identiﬁed as a risk factor for mortality in ICU
patients. Cunningham et al., stated that mortality in critically
ill COPD might be related to other components of the disease
such as cachexia that may affect adversely the immune
response [24].There is some limitation of our study related to single cen-
ter study and limited number of cases as regards studying of
mortality so more work in this ﬁeld is needed.
Conclusion
Ventilator associated pneumonia VAP remains a common
complication of ventilator support for patients with
AECOPD and is associated with high morbidity and mortality.
Elderly, late onset VAP, re-intubation and prolonged use of
antibiotics were predictors of mortality in VAP patients with
AECOPD.
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